Getting Access episode artwork

EPISODE · Apr 27, 2022 · 21 MIN

Getting Access

from The Syneos Health Podcast · host Jeffrey Stewart and Jon Haas

The medicine may be “transformational,” but doctors won’t write the script if payers don’t reimburse.And there’s a veritable alphabet soup of players – everything from KAMs to NAMs, MSLs to MSOLs, PBMs to IDNs, and more – involved in negotiating the path to reimbursement and, ultimately, access for innovative therapies when they hit the market. Jon Haas, Senior Director, Market Access at Syneos Health, discusses the complex process, how companies can best position their product for access and what really matters to payers in the long run.For more on value and access in biopharma, check out:How Competition Affects Market Access for Rare Disease Therapeutics, Part 1How Competition Affects Market Access for Rare Disease Therapeutics, Part 2Future-Forward Planning: What Drug and Device Manufacturers Need to Know About Preventive Drug Lists2021 Update: Non-Personal Promotion: What Do Payers Want?​The Other Path to Access: Strategies for Direct Employer Engagement​The Syneos Health Podcast: Trade and Distribution in Pharma: It's Complicated​What to Expect on Drug Pricing in the Democratic Trifecta​ If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at [email protected] views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected]

The medicine may be “transformational,” but doctors won’t write the script if payers don’t reimburse. And there’s a veritable alphabet soup of players – everything from KAMs to NAMs, MSLs to MSOLs, PBMs to IDNs, and more – involved in negotiating the path to reimbursement and, ultimately, access for innovative therapies when they hit the market. Jon Haas, Senior Director, Market Access at Syneos Health, discusses the complex process, how companies can best position their product for acc...

NOW PLAYING

Getting Access

0:00 21:13

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Syneos Health Podcast?

This episode is 21 minutes long.

When was this The Syneos Health Podcast episode published?

This episode was published on April 27, 2022.

What is this episode about?

The medicine may be “transformational,” but doctors won’t write the script if payers don’t reimburse.And there’s a veritable alphabet soup of players – everything from KAMs to NAMs, MSLs to MSOLs, PBMs to IDNs, and more – involved in negotiating the...

Can I download this The Syneos Health Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!